Home » Newsletters » BioWorld Asia

BioWorld Asia

Jan. 10, 2001

View Archived Issues

MorphoSys Enters EUR22M Deal With Centocor Around HuCAL

SHIP2 Gene Makes Waves As Potential Type II Diabetes Target

European Parliament Report Calls For Separation Of Biotech Areas

Xantos Formed Around Platform To Perform Functional Genomics

GenOdyssee Applies For Patents Covering Genetic Variants Method

Other News To Note

MediGene's Genital Warts Drug Enters Phase III Clinical Trials

Combio Spun Off From Carlsberg To Develop Chemistry Platform

Oxford BioMedica Moving To LSE Following TroVax Trial Approval

Eurofins Beefing Up Detection Business Through Acquisitions

Phytopharm Sees Encouraging Results In Phase I P54 Study

PhotoCure Reports Skin Cancer Cures In Phase III PDT Trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....